Keystone Labs Court-Ordered To Halt OTC Drug Manufacturing; Cosmetics Not Affected, It Says
This article was originally published in The Rose Sheet
Executive Summary
Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.
You may also be interested in...
FDA Appears To Be Prepping For Cosmetics Regulatory Changes, Ingredient Review
Proposed regulatory reform legislation in the Senate would require FDA to review the safety of cosmetics ingredients, taking into account evaluations conducted by accredited third parties. In August, FDA requested quotes from the contractor community for developing a cosmetic hazard and risk assessment protocol and optional certification program “to show compliance with the protocol.”
FDA Consumer Health Product Recalls For May 4-25, 2016
Recalls reported by FDA for OTC drugs, nutritionals and personal care products.
ICCR Ushers Forth Updated Cosmetic GMP Guidelines From FDA
FDA’s draft revision of Cosmetic Good Manufacturing Practices takes into account international consensus formed through harmonization efforts under the International Cooperation on Cosmetics Regulations, says the agency. The recommendations update guidelines created in 1997 and revised in 2008.